{"text": "Supplementary Material\n\nSupplemental Table S1: Long range PCR primers for CYP2D6 copy number assay Primer Sequence Position Strand 2D6dupl\u00adFa CCTGGGAAGGCCCCATGGAAG chr22:42,522,003-42,522,023 negative 2D6dupl\u00adRa CAGTTACGGCAGTGGTCAGCT chr22:42,530,646-42,530,666 positive 5\u00ad2D6delb CACCAGGCACCTGTACTCCTC chr22:42,534,666-42,534,686 negative 3\u00ad2D6delb CAGGCATGAGCTAAGGCACCCAGAC chr22:42,519,025-42,519,049 positive DPKupab GTTATCCCAGAAGGCTTTGCAGGCTTCA chr22:42,527,113-42,527,140 negative DPKlowab GCCGACTGAGCCCTGGGAGGTAGGTA chr22:42,522,040-42,522,065 Positive a PCR amplification with these primers results in 5.1kb product if no duplication is present, and 5.1 and 3.5 kb products if a duplication is present. b PCR amplification with these primers results in 5.1 kb product if no deletion present, and 5.1 and 3.5 kb products if a deletion is present. Page 25 of 31 \n\nSupplemental Table S2: Variants used to identify CYP2D6 star alleles rsID rs7692 58 rs28371 696 rs1065 852 rs5030 862 rs72549 357 rs50308 63 rs28371 706 rs5030 655 rs1135 824 rs5030 865 rs3892 097 rs28371 717 rs35742 686 rs5030 656 rs1694 7 rs5030 867 rs28371 725 rs59421 388 rs1135 840 Updated rsID rs77467 1100 rs20137 7835 HG19 chr22 Locus 42526 763 425267 17 42526 694 42526 670 4252665 6 4252591 2 425257 72 42525 085 42525 044 42525 035 42524 947 425243 10 425242 43 42524 175 42523 943 42523 858 425238 05 425236 10 42522 613 Reference C C G C C C G CA T C C C CT CCTT A T C C G *1 G C *2 *3 C G C *3B C C G C *4 A T G *5 *6 C G C *6C C G *7 G G C *8 A *9 C G C *10 A G *11 G *12 T *14A A T *14B T *15 CA G C *17 A *29 T *33 A G C *35 T *41 T *46 T - No alleles, as *5 is deletion of the CYP2D6 gene Page 26 of 31 \n\nSupplemental Table S3: Genotype and phenotype characteristics of study cohort Diplotype Number of Individuals Frequency (%) Phenotype CYP2D6 *1/*2xN 4 1.6 UM CYP2D6 *1/*1xN 1 0.4 UM CYP2D6 *1xN/*2 1 0.4 UM CYP2D6 *1/*1 39 15.2 NM CYP2D6 *1/*2 37 14.4 NM CYP2D6 *1/*4 34 13.2 NM CYP2D6 *2/*4 17 6.6 NM CYP2D6 *1/*41 14 5.4 NM CYP2D6 *1/*35 10 3.9 NM CYP2D6 *2/*41 9 3.5 NM CYP2D6 *1/*9 8 3.1 NM CYP2D6 *1/*17 6 2.3 NM CYP2D6 *1/*5 6 2.3 NM CYP2D6 *1/*3 4 1.6 NM CYP2D6 *2/*2 4 1.6 NM CYP2D6 *1/*29 3 1.2 NM CYP2D6 *2/*6 3 1.2 NM CYP2D6 *35/*41 3 1.2 NM CYP2D6 *2/*17 2 0.8 NM CYP2D6 *2/*35 2 0.8 NM CYP2D6 *2/*5 2 0.8 NM CYP2D6 *3/*35 2 0.8 NM CYP2D6 *4/*35 2 0.8 NM CYP2D6 *1/*10 1 0.4 NM CYP2D6 *1/*33 1 0.4 NM CYP2D6 *1/*6 1 0.4 NM CYP2D6 *10/*35 1 0.4 NM CYP2D6 *10/*46 1 0.4 NM CYP2D6 *1xN/*4 1 0.4 NM CYP2D6 *2/*10 1 0.4 NM CYP2D6 *2/*29 1 0.4 NM CYP2D6 *2/*3 1 0.4 NM CYP2D6 *2/*9 1 0.4 NM CYP2D6 *35/*35 1 0.4 NM CYP2D6 *17/*5 3 1.2 IM CYP2D6 *4/*10 3 1.2 IM CYP2D6 *4/*41 3 1.2 IM CYP2D6 *4/*9 3 1.2 IM CYP2D6 *3/*41 2 0.8 IM CYP2D6 *10/*5 1 0.4 IM Page 27 of 31 \n\nCYP2D6 *4/*17 1 0.4 IM CYP2D6 *4/*29 1 0.4 IM CYP2D6 *41/*5 1 0.4 IM CYP2D6 *4/*4 7 2.7 PM CYP2D6 *3/*4 5 1.9 PM CYP2D6 *3/*5 1 0.4 PM CYP2D6 *4/*4xN 1 0.4 PM CYP2D6 *4/*6 1 0.4 PM Page 28 of 31 \n\nSupplemental Table S4: Adverse event characteristics and frequencies by metabolizer status Adverse Event (AE) Individuals with AE n=104 (%) Poor Metabolizers with AE, n=15 (%) Intermediate Metabolizers with AE, n=18 (%) Normal Metabolizers with AE, n=218 (%) Ultrarapid Metabolizers with AE, n=6 (%) Weight change 23 (8.9) 0 5 (27.8) 17 (7.8) 1 (16.7) Extrapyramidal symptoms 16 (6.2) 1 (6.7) 0 14 (6.4) 1 (16.7) Hypersomnia or sedation 15 (5.8) 2 (13.3) 2 (11.1) 11 (5) 0 Hyperphagia or increased appetite 11 (4.3) 0 1 (5.6) 10 (4.6) 0 Elevation of blood glucose 5 (1.9) 0 1 (5.6) 4 (1.8) 0 Abnormal thyroid function test 5 (1.9) 0 2 (11.1) 3 (1.4) 0 Hyperprolactinemia or gynecomastia 4 (1.6) 0 2 (11.1) 2 (0.9) 0 Hyper salivation 4 (1.6) 0 1 (5.6) 3 (1.4) 0 Elevation of serum lipids 3 (1.2) 0 1 (5.6) 2 (0.9) 0 QTc prolongation 3 (1.2) 0 1 (5.6) 2 (0.9) 0 Behavioral concerns 3 (1.2) 0 1 (5.6) 2 (0.9) 0 Anxiety or nervousness 2 (0.8) 0 0 2 (0.9) 0 Constipation 2 (0.8) 0 0 2 (0.9) 0 Precocious puberty 2 (0.8) 0 0 2 (0.9) 0 Muscle cramps 1 (0.4) 1 (6.7) 0 0 0 Headache 1 (0.4) 0 0 1 (0.5) 0 Hot flashes 1 (0.4) 0 0 0 1 (16.7) Fainting episode 1 (0.4) 0 0 0 1 (16.7) Bruising 1 (0.4) 0 1 (5.6) 0 0 Oculogyric crisis 1 (0.4) 1 (6.7) 0 0 0 Page 29 of 31 \n\nSupplemental Table S5: Cohort characteristics by adverse event presence Characteristics Adverse Event (Frequency (%) or median (IQR)) No Adverse Event (Frequency (%) or median (IQR)) P value* Age 8.4 (6.3-10.7) 8.3 (6.3-10.3) 0.8 Male sex 57 (75) 131 (72.4) 0.8 Race 0.04 White 64 (84.2) 153 (84.5) African-American 6 (7.9) 23 (12.7) Asian/Pacific islander 1 (1.3) 4 (2.2) Unknown 4 (5.3) 1 (0.6) Native American 1 (1.3) 0 Ethnicity 0.3 Hispanic 1 (1.3) 5 (2.8) Non-Hispanic 72 (94.7) 174 (96.1) Unknown 3 (4) 2 (1.1) Specific indication for risperidone Aggression 45 (59.2) 80 (44.2) 0.03 Behavioral problems 20 (26.3) 59 (32.6) 0.4 Agitation 16 (21.1) 26 (14.4) 0.2 Irritability 25 (32.9) 38 (21) 0.06 Self-injurious behaviors 25 (32.9) 20 (11.1) <0.001 Baseline dosing regimen of risperidone (mg/day) 0.5 (0.4-1) 0.5 (0.5-1) 0.6 *P values from Kruskal-Wallis test for continuous variables and Fisher s exact for categorical variables. IQR Interquartile Range Page 30 of 31 "}